Repeated Application of Gene Therapy in CF Patients

NCT ID: NCT01621867

Last Updated: 2015-10-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 130 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2014-05-31

Brief Summary

Cystic fibrosis is a genetic condition where epithelial cells, including from the respiratory tract, have an abnormal function of a surface protein, the cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from abnormal gene expression. The trial will assess the clinical efficacy, safety & tolerability and gene expression following repeated nebulised doses of a gene product coding for a normal CFTR protein, with the primary outcome of the trial assessing lung function.

Detailed Description

Cystic fibrosis (CF), a common, genetically inherited disease, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene encodes the CFTR protein, which is expressed on the apical surface of epithelial cells, and which has many functions, the most important of which is thought to be ion transport. Abnormal ion transport leads to thick secretions in the airways, infection, inflammation and eventually irreversible lung damage. There is currently no treatment that halts the natural progression of the disease; all available successful therapies merely slow the rate of decline in clinical condition.

To date, no viral gene transfer agents retain efficacy upon repeated administration. Our study will assess the safety and efficacy of a lipid-mediated vector harbouring a normal CFTR gene in repeated nebulised administrations. We have completed a single dose safety study which evaluated the safety and gene expression of a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis.

This trial is will randomise 130-patients to receive either a gene product (pGM169/GL67A)encoding for CFTR or placebo in a double-blinded fashion. All subjects will receive 12 doses of nebulised gene therapy at intervals of 4 weeks over a 48 week period. After dose 12 there will be 2 formal follow up visits, at 14 and 28 days post-dose. In addition, patients will be followed up long-term.

Subgroups of patients will be enrolled for gene expression measurement in both nose (at least n=20) and lower airway via bronchoscopy (at least n=20).

The primary outcome of the trial is to evaluate the relative change in predicted Forced Expiratory Volume in 1-second (FEV1) after 12-doses. Secondary outcome measures will assess the efficacy of the gene product (by assessment of patients' physiological function, serological indices, radiological appearances of the lungs and self-reported assessment of quality of life), on the degree of gene expression and on the product safely.

Conditions

Cystic Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

pGM169/GL67A (CFTR Gene/Lipid Vector)

Group Type: ACTIVE_COMPARATOR

pGM169/GL67A

Intervention Type: DRUG

5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)

Interventions

pGM169/GL67A

5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)

Intervention Type: DRUG

Placebo

5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Cystic fibrosis confirmed by sweat testing or genetic analysis

2. Males and females aged 12 years and above

3. Forced expiratory volume in the 1st second (FEV1) between 50 & 90% predicted inclusive (Stanojevic reference equations).

4. Clinical stability at screening defined by:

1. Not on any additional antibiotics (excluding routine, long-term treatments) for the previous 2 weeks

2. No increase in symptoms such as change in sputum production/colour, increased wheeze or breathlessness over the previous 2 weeks

3. No change in regular respiratory treatments over the previous 4 weeks

4. If any of these apply, entry into the study can be deferred

5. Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter (as stated in GTAC guidelines)

6. If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose (nebulised doses only)

7. Written informed consent obtained

8. Permission to inform their general practitioner of participation in study

Exclusion Criteria

1. Infection with Burkholderia cepacia complex organisms, MRSA or M. abscessus

2. Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds) (nasal cohort only)

3. Chloride secretory response on nasal PD of > 5 mV (nasal cohort only; will only be known after first measurement)

4. Acute upper respiratory tract infection within the last 2 weeks (entry can be deferred)

5. Previous spontaneous pneumothorax without pleurodesis (bronchoscopic subgroup only)

6. Recurrent severe haemoptysis (bronchoscopic subgroup only)

7. Current smoker

8. Significant comorbidity including:

1. Moderate/severe CF liver disease (varices or significant, sustained elevation of transaminases: ALT/ AST>100 IU/l)

2. Significant renal impairment (serum creatinine > 150 mmol/l)

3. Significant coagulopathy (bronchoscopic group only)

9. Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations

10. Pregnant or breastfeeding

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Edinburgh

OTHER

Sponsor Role: collaborator

University of Oxford

OTHER

Sponsor Role: collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

Sponsor Role: collaborator

Imperial College London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Alton, MD, FMedSci

Role: STUDY_DIRECTOR

Imperial College London

Jane Davies, MD

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Uta Griesenbach, PhD

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Steve Hyde, MA, DPhil

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Deborah Gill, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Chris Boyd, PhD

Role: PRINCIPAL_INVESTIGATOR

Edinburgh University

David Porteous, FMedSci

Role: PRINCIPAL_INVESTIGATOR

Edinburgh University

Alastair Innes, PhD

Role: PRINCIPAL_INVESTIGATOR

Edinburgh University

Steve Cunningham, PhD

Role: PRINCIPAL_INVESTIGATOR

Edinburgh University

Locations

Western General Hospital

Edinburgh, , United Kingdom

Royal Hospital for Sick Children

Edinburgh, , United Kingdom

Royal Brompton Hospital

London, , United Kingdom

Countries

United Kingdom

References

Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947-54. doi: 10.1016/s0140-6736(98)06532-5.

Reference Type: RESULT

PMID: 10459902 (View on PubMed)

Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27.

Reference Type: DERIVED

PMID: 31215818 (View on PubMed)

Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DDS, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JSR, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.

Reference Type: DERIVED

PMID: 26149841 (View on PubMed)

Related Links

http://www.cfgenetherapy.org.uk/

The UK Cystic Fibrosis Gene Therapy Consortium

Other Identifiers

2011-004761-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ICL/CRO-1881

Identifier Type: -

Identifier Source: org_study_id